by Rakovina Therapeutics | Feb 26, 2025 | Uncategorized
DOWNLOAD Strategic Funding Led by Nimbus Synergies, Backed by Merck GHI, to Accelerate Al-Powered Collaborations VANCOUVER, British Columbia, Feb. 26, 2025 — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer...
by Rakovina Therapeutics | Feb 6, 2025 | Uncategorized
Vancouver, British Columbia, Feb 6, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, announces continued advancement of its AI-driven drug discovery program....
by Rakovina Therapeutics | Jan 31, 2025 | Uncategorized
VANCOUVER, British Columbia, Jan. 30, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce that its common shares are now listed...
by Rakovina Therapeutics | Jan 29, 2025 | Uncategorized
January 29, 2025 – Vancouver, British Columbia – Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced its participation in the...
by Rakovina Therapeutics | Jan 22, 2025 | Uncategorized
Vancouver, British Columbia, January 22, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront of AI-driven drug discovery, yesterday commented on the announcement of a $500 billion private-sector investment into AI...
by Rakovina Therapeutics | Jan 13, 2025 | Uncategorized
VANCOUVER, British Columbia, Jan. 13, 2025 — Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the successful achievement of a...